Market closedNon-fractional

AlloVir/ALVR

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About AlloVir

AlloVir Inc is a late clinical-stage cell therapy company. The company focuses on developing innovative allogeneic T-cell therapies to combat viral diseases. Their proprietary VST therapy platform enables the creation of off-the-shelf VSTs, addressing the urgent medical need for treating patients with limited viral disease treatment options. With a singular focus on research, development, and commercialization, the company's platform targets 11 devastating viruses, with posoleucel being the lead candidate addressing six viruses. Operating within one segment, the company is dedicated to preventing and treating severe viral-associated diseases through off-the-shelf VST therapies.

Ticker

ALVR

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Waltham, United States

Employees

15

AlloVir Metrics

BasicAdvanced
$83M
Market cap
-
P/E ratio
-$1.64
EPS
0.78
Beta
-
Dividend rate
$83M
0.78
18.48
18.379
13.324
15.229
-51.82%
-114.36%
0.69
0.69
-0.588
-16.99%
-9.05%

What the Analysts think about AlloVir

Analyst Ratings

Majority rating from 5 analysts.
Sell

AlloVir Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0.00% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$30M
-49.33%
Profit margin
0.00%
NaN%

AlloVir Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 65.96%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.48
-$0.39
-$0.36
-$0.26
-
Expected
-$0.45
-$0.42
-$0.43
-$0.16
-$0.09
Surprise
6.67%
-6.25%
-15.89%
65.96%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for AlloVir stock?

AlloVir (ALVR) has a market cap of $83M as of July 06, 2024.

What is the P/E ratio for AlloVir stock?

The price to earnings (P/E) ratio for AlloVir (ALVR) stock is 0 as of July 06, 2024.

Does AlloVir stock pay dividends?

No, AlloVir (ALVR) stock does not pay dividends to its shareholders as of July 06, 2024.

When is the next AlloVir dividend payment date?

AlloVir (ALVR) stock does not pay dividends to its shareholders.

What is the beta indicator for AlloVir?

AlloVir (ALVR) has a beta rating of 0.78. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy or sell AlloVir stock

Buy or sell AlloVir stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing